THE US Food and Drug
Administration has granted
approval to Inflectra (inflimax-dyyb)
for a range of indications.
Inflectra is a biosimilar to Janssen
Biotech’s Remicade (infliximab)
which was first licensed in 1988.
Under the new FDA approval
Inflectra can be prescribed for
the treatment of Crohn’s disease,
ulcerative colitis, rheumatoid
arthritis, ankylosing spondylitis,
psioratic arthritis and chronic
severe plaque psoriasis.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Apr 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.